Relay Therapeutics reports promising Phase 2 results for zovegalisib; Eli Lilly leads R&D performance ranking

Relay Therapeutics announced positive Phase 2 data for its experimental drug zovegalisib, which targets rare diseases that cause abnormal blood vessel development. The company said the results were encouraging and could support further development of the therapy.

The news lifted Relay Therapeutics' share price, with the stock rising about 9% in pre‑market trading following the announcement.

Separately, the consulting firm IDEA Pharma released its annual ranking of pharmaceutical companies based on R&D performance. Eli Lilly topped the list in both the innovation metric, which weighs revenue from new drugs, and the invention metric, which considers the number of drugs in development and R&D spending. This marks the first time a single company has led both categories in the ranking.